REPRIEVE final results: What does it mean for guidelines in low‐ and middle‐income countries?

Abstract Introduction The REPRIEVE study demonstrated significant reductions in major adverse cardiovascular events (MACE) with pitavastatin among people living with HIV (PWH) with low to moderate cardiovascular risk. Most MACE events occurred in higher‐income countries, raising important considerat...

Descripció completa

Dades bibliogràfiques

Autors principals:	Simiso Sokhela, Jennifer M. Manne‐Goehler, Samanta Lalla‐Edward, Mark J. Siedner, Mohammed K. Ali, Andrew Hill, Aaloke Mody, Anton Pozniak, Jeremy Nel, W. D. Francois Venter
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2025-06-01
Col·lecció:	Journal of the International AIDS Society
Matèries:	cardiovascular HIV MACE pitavastatin REPRIEVE statin
Accés en línia:	https://doi.org/10.1002/jia2.26525
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!